Developing a curative gene therapy for Crigler-Najjar syndrome.
The CureCN project has ended.
1.1.2018 – 31.12.2023


6.25 M €


11 Partners from 6 countries


Project Leaflet

The Vision of CureCN

The overall vision of the European research project CureCN was to provide a curative gene therapy for the ultra-rare Crigler-Najjar syndrome (CN). CN is a life-threatening, so far incurable liver disease that affects about one in a million individuals at birth.

The CureCN consortium joined forces to prove the safety and efficacy of gene therapy in a clinical trial and to make the treatment available to patients. The project was funded by the European Framework Programme for Research and Innovation Horizon 2020 with a total budget of € 6.25 million.

While the project came to a close at the end of 2023, initial results of the study have found that the treatment is safe, well tolerated by patients, and shows promising signs of curing the disease.

Read more


The CureCN consortium brought together 11 European partners from academia, hospitals, healthcare companies and patient organisations to fight the so far incurable liver disease Crigler-Najjar (CN). Together, they set out to validate a gene therapy within a clinical trial to provide the first curative treatment against CN.

Read more

Latest News


Do you want to stay up to date about the CureCN project activities? Sign up here to receive the next newsletter issues.

Subscribe Archive

Information for Patients

CureCN was a patient-driven research endeavour comprising all active Crigler-Najjar patient organisations in Europe. You are a patient, a family member or a friend of a person living with CN? Please find more information about the project and how CureCN and the patient organisations involved have provided support and advice to improve the quality of life for people with CN.

Read more